These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 33676073

  • 1. Cannabidiol (CBD) and other drug use among young adults who use cannabis in Los Angeles.
    Fedorova EV, Wong CF, Ataiants J, Iverson E, Conn BM, Lankenau SE.
    Drug Alcohol Depend; 2021 Apr 01; 221():108648. PubMed ID: 33676073
    [Abstract] [Full Text] [Related]

  • 2. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
    Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS.
    Psychopharmacology (Berl); 2019 Sep 01; 236(9):2713-2724. PubMed ID: 31044290
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users.
    Spindle TR, Cone EJ, Goffi E, Weerts EM, Mitchell JM, Winecker RE, Bigelow GE, Flegel RR, Vandrey R.
    Drug Alcohol Depend; 2020 Jun 01; 211():107937. PubMed ID: 32247649
    [Abstract] [Full Text] [Related]

  • 4. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
    Trevitt BT, Bailey S, Mills L, Arkell TR, Suraev A, McGregor IS, Lintzeris N.
    PLoS One; 2024 Jun 01; 19(2):e0297092. PubMed ID: 38354169
    [Abstract] [Full Text] [Related]

  • 5. A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
    Solowij N, Broyd S, Greenwood LM, van Hell H, Martelozzo D, Rueb K, Todd J, Liu Z, Galettis P, Martin J, Murray R, Jones A, Michie PT, Croft R.
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb 01; 269(1):17-35. PubMed ID: 30661105
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.
    Morgan CJ, Freeman TP, Schafer GL, Curran HV.
    Neuropsychopharmacology; 2010 Aug 01; 35(9):1879-85. PubMed ID: 20428110
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
    Highet BH, Lesser ER, Johnson PW, Kaur JS.
    Am J Hosp Palliat Care; 2020 Aug 01; 37(8):589-593. PubMed ID: 31986898
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.
    Gibson LP, Mueller RL, Winiger EA, Klawitter J, Sempio C, Williams S, Bryan AD, Bidwell LC, Hutchison KE.
    Cannabis Cannabinoid Res; 2024 Feb 01; 9(1):320-334. PubMed ID: 36378267
    [Abstract] [Full Text] [Related]

  • 14. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
    Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL.
    Neuropsychopharmacology; 2016 Jul 01; 41(8):1974-82. PubMed ID: 26708108
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
    Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, Wingham G, Lewis S, Curran HV.
    Psychol Med; 2012 Feb 01; 42(2):391-400. PubMed ID: 21798112
    [Abstract] [Full Text] [Related]

  • 18. Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial.
    Lorenzetti V, McTavish E, Broyd S, van Hell H, Thomson D, Ganella E, Kottaram AR, Beale C, Martin J, Galettis P, Solowij N, Greenwood LM.
    Cannabis Cannabinoid Res; 2024 Aug 01; 9(4):e1108-e1121. PubMed ID: 37603080
    [Abstract] [Full Text] [Related]

  • 19. Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study.
    Bidwell LC, Martin-Willett R, Skrzynski C, Lisano J, Ortiz Torres M, Giordano G, Hutchison KE, Bryan AD.
    Cannabis Cannabinoid Res; 2024 Aug 01; 9(4):1015-1027. PubMed ID: 38252547
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.